Home › Linfoma di Burkitt › Tennessee
Studi clinici su Linfoma di Burkitt nello stato di Tennessee
10 studi su Linfoma di Burkitt cercano partecipanti presso sedi nello stato di Tennessee.
Città nello stato di Tennessee
Testo ufficiale dello studio (inglese)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- East Tennessee Childrens Hospital, Knoxville
- The Children's Hospital at TriStar Centennial, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
In reclutamentoFase 2
366 Days – 46 Years · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- East Tennessee Childrens Hospital, Knoxville
- Saint Jude Children's Research Hospital, Memphis
- The Children's Hospital at TriStar Centennial, Nashville
- e altri 1
In reclutamentoFase 2
365 Days · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- East Tennessee Childrens Hospital, Knoxville
- The Children's Hospital at TriStar Centennial, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
In reclutamentoFase 2
Età da 1 a 30 · Tutti i sessi · Aggiornato il 1 set 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- T C Thompson Children's Hospital, Chattanooga
- East Tennessee Childrens Hospital, Knoxville
- The Children's Hospital at TriStar Centennial, Nashville
- e altri 1
In reclutamentoFase 3
365 Days – 25 Years · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT03959085Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
In reclutamentoFase 1/2
Età da 13 a 90 · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT06533579Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Research Site, Franklin
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 13 lug 2026 · NCT07109219CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia
- St. Jude Children's Research Hospital, Memphis
In reclutamentoFase 1
Fino a 21 anni · Tutti i sessi · Aggiornato il 19 mag 2026 · NCT06777979CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions
- St. Jude Children's Research Hospital, Memphis
In reclutamentoStudio osservazionale
Tutte le età · Tutti i sessi · Aggiornato il 29 apr 2026 · NCT07048535Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- Sarah Cannon - HCA Research Institute, Nashville
In reclutamentoFase 1/2
Età da 15 a 50 · Tutti i sessi · Aggiornato il 9 set 2025 · NCT04150497Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- TriStar Bone Marrow Transplant, Nashville
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 nov 2024 · NCT06034275Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.